Netherlands· NL-648e35205211

Optiray 350, oplossing voor injectie of infusie, 350 mg I/ml

A ioversol product containing joversol, registered in Netherlands by Guerbet. The same ATC class is registered in 14 of our 19 countries.

ATC V08AB07

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about joversolAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ioversol is registered in 14 of 19 countries.

Countries holding a registration under ATC V08AB07 (ioversol), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search ioversol products by name

Ioversol · ATC V08AB07

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Ireland
Japan
Netherlands
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: JOVERSOL
Manufacturer: Guerbet
Country: Netherlands (NL)
ATC code: V08AB07
ATC class: Ioversol
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
15718

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

188 interactions on record for ioversol.

Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check ioversol against other medicines How interaction checks work

Ioversol · interactions on record

188 records

94 severe
55 moderate
39 info

Most severe, free to view

NeomycinA07AA01severe
StreptomycinA07AA04severe
Polymyxin BA07AA05severe
Amphotericin BA07AA07severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ioversol in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ioversol products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

Austria · Optiray
Belgium · Optiject, Optiray
Czechia · Optiray
Germany · Optiray
Denmark · Optiray
Spain · Optiray, Optiray Ultraject
Finland · Optiray
France · Optiject, Optiray
United Kingdom (Northern Ireland) · Optiray
Greece · Optiray
Croatia · Optiray
Hungary · Optiray
Ireland · Optiray
Italy · Optiray
Luxembourg · Optiject, Optiray
Norway · Optiray
Poland · Optiray
Portugal · Optiray
Romania · Optiray
Sweden · Optiray
Slovakia · Optiray

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/8b88d51f-357c-49e4-9015-1660381cefc5
GET /v1/drugs/8b88d51f-357c-49e4-9015-1660381cefc5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie of infusie",
  "route": "Intra-arterieel gebruik, Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h15718_smpc.pdf",
  "strength": null,
  "atc_label": "Ioversol",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg15718",
  "excipients": [
    "DINATRIUMCALCIUMEDETAAT, GEHYDRATEERD (E 385)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "TROMETAMOL",
    "TROMETAMOLHYDROCHLORIDE",
    "WATER, GEZUIVERD"
  ],
  "substances": [
    "JOVERSOL"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h15718.pdf",
  "authorised_at": "1992/05/13",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "15718",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about ioversol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console